Contents

Contents

• Commentaries

  • A National Cancer Clinical Trials System for Targeted Therapies

    By John Mendelsohn

    Science Translational Medicine23 Mar 2011 : 75cm8 Full AccessRestricted Access

    Clinical cancer research requires a well-supported and efficient national clinical trials network that engages in innovative trials of modern cancer therapies.

    • Abstract
    • Full Text
    • PDF

  • Accrual to Cancer Clinical Trials in the Era of Molecular Medicine

    By Richard L. Schilsky

    Science Translational Medicine23 Mar 2011 : 75cm9 Full AccessRestricted Access

    In the testing of targeted cancer therapies, new issues can complicate the decision by patients or providers to participate in clinical trials.

    • Abstract
    • Full Text
    • PDF

• Research Articles

  • Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis

    By Fang Fang, Sevin Turcan, Andreas Rimner, Andrew Kaufman, Dilip Giri, Luc G. T. Morris, Ronglai Shen, Venkatraman Seshan, Qianxing Mo, Adriana Heguy, Stephen B. Baylin, Nita Ahuja, Agnes Viale, Joan Massague, Larry Norton, Linda T. Vahdat, Mary Ellen Moynahan, Timothy A. Chan

    Science Translational Medicine23 Mar 2011 : 75ra25 Full AccessRestricted Access

    Breast cancer methylomes contribute to metastatic potential, modulate the metastasis transcriptome, and predict disease outcome.

    • Editor's Summary
    • Abstract
    • Full Text
    • PDF

  • Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

    By Lecia V. Sequist, Belinda A. Waltman, Dora Dias-Santagata, Subba Digumarthy, Alexa B. Turke, Panos Fidias, Kristin Bergethon, Alice T. Shaw, Scott Gettinger, Arjola K. Cosper, Sara Akhavanfard, Rebecca S. Heist, Jennifer Temel, James G. Christensen, John C. Wain, Thomas J. Lynch, Kathy Vernovsky, Eugene J. Mark, Michael Lanuti, A. John Iafrate, Mari Mino-Kenudson, Jeffrey A. Engelman

    Science Translational Medicine23 Mar 2011 : 75ra26 Full AccessRestricted Access

    Lung cancers undergo dynamic genetic and histological changes upon developing resistance to EGFR inhibitors.

    • Editor's Summary
    • Abstract
    • Full Text
    • PDF

• Editors' Choice

  • Two Peas in a Pod

    By Ruth M. Farrell

    Science Translational Medicine23 Mar 2011 : 75ec38 Full AccessRestricted Access

    Eclampsia and preeclampsia may be branches off a common event that takes place at the utero-placenta junction.

    • Full Text

  • Strike Three: Positive Progress on the Triple Negative

    By Diane Gesty-Palmer

    Science Translational Medicine23 Mar 2011 : 75ec39 Full AccessRestricted Access

    Triple-negative breast cancers are driven by—surprise!—a tumor suppressor that regulates protein tyrosine kinases.

    • Full Text

  • Genetic Tug of War in the Immune System

    By Timothy B. Niewold

    Science Translational Medicine23 Mar 2011 : 75ec40 Full AccessRestricted Access

    A genome-wide association study uncovers loci that confer risk for an immune-mediated kidney disease.

    • Full Text

  • The Hunt for Red October

    By Srini Tridandapani

    Science Translational Medicine23 Mar 2011 : 75ec41 Full AccessRestricted Access

    Investigators have improved medical sonar (ultrasound) to hunt down and track elusive cancer cells.

    • Full Text

• Podcast

  • Science Translational Medicine Podcast: 23 March 2011

    By Timothy Chan, Angela Colmone

    Science Translational Medicine23 Mar 2011 : 75pc4 Full AccessRestricted Access

    A conversation with Timothy Chan about a new way to predict breast cancer metastasis.

    • Abstract